Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 2,911 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Secondary Hypogonadism
Interventions: Androxal, AndroGel, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more

Conditions: Huntington's Disease
Interventions: Pridopidine, Placebo; Drug · Other
Lead sponsor: Prilenia; Industry
Eligibility: 21 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more

Conditions: Celiac Disease
Interventions: larazotide acetate, Placebo; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Diego, California • Boston, Massachusetts + 6 more

Conditions: Severe Hypertriglyceridemia
Interventions: AKR-963; Drug
Lead sponsor: Trygg Pharma, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Breast Cancer
Interventions: Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 56
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more

Conditions: Pain
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 18 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 16
States / cities: Little Rock, Arkansas • Long Beach, California • Colorado Springs, Colorado + 10 more

Conditions: Colonoscopy
Interventions: Magnesium Citrate Capsules, Polyethylene Glycol 3350, Dulcolax Tablets; Dietary Supplement · Other
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Friedreich's Ataxia
Interventions: RT001, Placebo; Drug
Lead sponsor: Biojiva LLC; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more

Conditions: Essential Tremor
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 26
States / cities: Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more

Conditions: Nonalcoholic Fatty Liver
Interventions: PXL770, Placebo Oral Capsule; Drug
Lead sponsor: Poxel SA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 15
States / cities: Los Angeles, California • Gainesville, Florida • Ocoee, Florida + 11 more

Conditions: ADHD
Interventions: Placebo, 100mg SPN-812, 200mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more

Conditions: Recurrent Clostridium Difficile Infection
Interventions: Lactobacillus acidophilus CL1285® and Lactobacillus casei, Placebo; Dietary Supplement
Lead sponsor: Bio-K Plus International Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Body Weight
Interventions: Aspirin 81mg, Aspirin 325mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Idiopathic Constipation
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 93
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 71 more

Conditions: Autism Spectrum Disorder, Autism
Interventions: L1-79; Drug
Lead sponsor: Yamo Pharmaceuticals LLC; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • Orange, California • San Rafael, California + 5 more

Conditions: Diabetic Neuropathic Pain
Interventions: ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg, Placebo, Duloxetine; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 8
States / cities: Anaheim, California • Walnut Creek, California • Milford, Connecticut + 5 more

Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
Interventions: Placebo, Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 4,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 58
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 55 more

Conditions: Congestive Heart Failure
Interventions: Lixivaptan, Placebo; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 25
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 22 more

Conditions: Prostate Cancer
Interventions: Galeterone, Enzalutamide; Drug
Lead sponsor: LTN PHARMACEUTICALS, INC.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 953 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 51
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more

Conditions: Schizophrenia
Interventions: placebo, Ziprasidone oral capsules; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 46
States / cities: Birmingham, Alabama • San Diego, California • Stanford, California + 34 more

Conditions: Multiple Sclerosis
Interventions: Isoxsuprine Hydrochloride, Placebo, Corticosteroid; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 49
States / cities: Birmingham, Alabama • Florence, Alabama • Fountain Valley, California + 44 more

Conditions: ADHD
Interventions: PRC-063 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Purdue Pharma, Canada; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

Body Weight, Aspirin Dose and Pro-resolving Mediators

Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation

A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

CANVAS - CANagliflozin cardioVascular Assessment Study

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)